Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

BACKGROUND: Dasatinib 100 mg once daily achieves intermittent BCR-ABL kinase inhibition and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. To better assess durability of response to and tolerability of dasatinib, data from a 2-year minimum follow...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shah, Neil P., Kim, Dong-Wook, Kantarjian, Hagop, Rousselot, Philippe, Llacer, Pedro Enrique Dorlhiac, Enrico, Alicia, Vela-Ojeda, Jorge, Silver, Richard T., Khoury, Hanna Jean, Müller, Martin C., Lambert, Alexandre, Matloub, Yousif, Hochhaus, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2010
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2817025/
https://ncbi.nlm.nih.gov/pubmed/20139391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.011452
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados